ATE208374T1 - Beta-laktam und cepham verbindungen und ihre herstellung - Google Patents

Beta-laktam und cepham verbindungen und ihre herstellung

Info

Publication number
ATE208374T1
ATE208374T1 AT93903302T AT93903302T ATE208374T1 AT E208374 T1 ATE208374 T1 AT E208374T1 AT 93903302 T AT93903302 T AT 93903302T AT 93903302 T AT93903302 T AT 93903302T AT E208374 T1 ATE208374 T1 AT E208374T1
Authority
AT
Austria
Prior art keywords
lactam
beta
optionally substituted
production
compound
Prior art date
Application number
AT93903302T
Other languages
English (en)
Inventor
Shigeru Torii
Hideo Tanaka
Mitio Sasaoka
Takashi Shiroi
Yutaka Kameyama
Original Assignee
Otsuka Kagaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP03031092A external-priority patent/JP3227497B2/ja
Priority claimed from JP03031192A external-priority patent/JP3265381B2/ja
Application filed by Otsuka Kagaku Kk filed Critical Otsuka Kagaku Kk
Application granted granted Critical
Publication of ATE208374T1 publication Critical patent/ATE208374T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
    • C07D205/095—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4 and with a nitrogen atom directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cephalosporin Compounds (AREA)
AT93903302T 1992-02-18 1993-02-03 Beta-laktam und cepham verbindungen und ihre herstellung ATE208374T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP03031092A JP3227497B2 (ja) 1992-02-18 1992-02-18 β−ラクタム化合物及びその製造法
JP03031192A JP3265381B2 (ja) 1992-02-18 1992-02-18 ２−置換メチル−３−セフェム化合物及びその製造法並びに２−エキソメチレンセフェム誘導体の製造法
PCT/JP1993/000131 WO1993016043A1 (en) 1992-02-18 1993-02-03 β-LACTAM COMPOUND AND CEPHEM COMPOUND, AND PRODUCTION THEREOF

Publications (1)

Publication Number Publication Date
ATE208374T1 true ATE208374T1 (de) 2001-11-15

Family

ID=26368636

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93903302T ATE208374T1 (de) 1992-02-18 1993-02-03 Beta-laktam und cepham verbindungen und ihre herstellung

Country Status (5)

Country Link
US (2) US5470972A (de)
EP (1) EP0592677B1 (de)
AT (1) ATE208374T1 (de)
DE (1) DE69331089T2 (de)
WO (1) WO1993016043A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
DK1141028T3 (da) 1998-12-23 2010-05-25 Pfizer Humane monoklonale antistoffer til CTLA-4
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
BRPI0116728B1 (pt) 2001-01-05 2018-10-30 Pfizer Inc. anticorpos para receptor de fator de crescimento i semelhante à insulina
US6578724B1 (en) * 2001-12-29 2003-06-17 United States Can Company Connector for use in packaging aerosol containers
BR0309254A (pt) * 2002-04-12 2005-03-01 Medarex Inc Uso de um anticorpo anti-ctla-4
DK1613750T3 (en) 2003-03-19 2016-01-18 Amgen Fremont Inc ANTIBODIES TO T CELL AND MUCINDO immunoglobulin-binding domain 1 (TIM-1) antigen and uses thereof
MX350383B (es) 2004-01-09 2017-09-04 Pfizer Anticuerpos contra madcam.
JP5139800B2 (ja) 2004-06-03 2013-02-06 ノビミューン エスアー 抗ｃｄ３抗体およびその使用方法
KR20070036130A (ko) * 2004-07-16 2007-04-02 화이자 프로덕츠 인코포레이티드 항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료
EP2567976B1 (de) 2005-03-23 2017-07-19 Genmab A/S Antikörper gegen CD38 zur Behandling von multiplem Myelom
EP3058955B1 (de) 2005-03-24 2019-05-29 Millennium Pharmaceuticals, Inc. Ov064-bindende antikörper und verfahren zu deren verwendung
CA2763671A1 (en) 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
CA2615460A1 (en) * 2005-08-08 2007-02-15 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
AR057807A1 (es) * 2005-09-12 2007-12-19 Novimmune Sa Formulaciones de anticuerpo anti-cd3
EP2548583A3 (de) 2005-11-10 2013-02-27 Curagen Corporation Verfahren zur behandlung von ovarial- und nierenkarzinom mit antikörpern gegen t-zell-immunglobulin-domänen- und mucin-domänen-1-(tim-1)-antigen
EP1954311A4 (de) 2005-12-07 2009-12-23 Medarex Inc Ctla-4-antikörper-dosierungseskalationstherapien
KR20090029184A (ko) * 2006-04-07 2009-03-20 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 항체 조성물 및 신생물성 질병의 치료 방법
CA2694034A1 (en) * 2007-07-27 2009-02-05 Pfizer Limited Antibody purification process by precipitation
EP2209474A4 (de) * 2007-10-09 2013-07-24 Sopharmia Inc Breitband-beta-lactamase-hemmer
WO2015164330A1 (en) 2014-04-21 2015-10-29 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
CA2759848C (en) 2009-05-05 2018-12-04 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
MY173390A (en) 2009-10-23 2020-01-22 Takeda Pharmaceuticals Co Anti-gcc antibody molecules and related compositions and methods
WO2012099871A1 (en) 2011-01-17 2012-07-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulation of lrch4 activity and therapeutic application thereof
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US9598496B2 (en) 2011-05-09 2017-03-21 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
KR102338833B1 (ko) 2012-02-06 2021-12-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
PL2918603T3 (pl) 2012-11-08 2019-01-31 University Of Miyazaki Przeciwciało zdolne do specyficznego rozpoznawania receptora transferyny
CN105101997B (zh) 2013-02-06 2018-11-09 印希彼有限合伙公司 不减少血小板和不减少血红细胞的cd47抗体及其使用方法
JP6403289B2 (ja) 2013-03-12 2018-10-10 グラディウス ファーマシューティカルズ コーポレーションＧｌａｄｉｕｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐｏｒａｔｉｏｎ 誘導体化３−スチリル−セファロスポリン
EP3033356B1 (de) 2013-08-14 2020-01-15 Sachdev Sidhu Antikörper gegen frizzled proteine und verwendung davon
JP6552412B2 (ja) 2013-09-05 2019-07-31 国立大学法人 宮崎大学 ヒトインテグリンａ６ｂ４と特異的に反応する抗体
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
CA2967379A1 (en) 2014-11-18 2016-05-26 Janssen Pharmaceutica Nv Cd47 antibodies, methods, and uses
CN109310885B (zh) 2016-03-15 2022-05-31 梅尔莎纳医疗公司 NaPi2b靶向抗体-药物缀合物及其使用方法
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
CN109310765A (zh) 2016-06-20 2019-02-05 领先基因生物技术股份有限公司 抗体-药物偶联物
WO2018049261A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
CN111032694B (zh) 2017-07-14 2024-03-08 辉瑞大药厂 针对madcam的抗体
EP3847196A4 (de) 2018-09-07 2023-01-04 ITabMed (HK) Limited Bispezifische antigenbindende proteine und verwendungen davon
CN113164594A (zh) 2018-11-20 2021-07-23 株式会社英仙蛋白质科学 向细胞内摄入铁的抑制剂
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
IT201900008376A1 (it) 2019-06-07 2020-12-07 Univ Degli Studi Di Modena E Reggio Emilia Anticorpi ad attività antitumorale
EP4026560A4 (de) 2019-09-04 2023-10-25 Perseus Proteomics Inc. Therapeutisches mittel für polyzythämie
CN114786718B (zh) 2019-11-27 2025-07-25 株式会社英仙蛋白质科学 癌性腹膜炎的治疗药
EP3909601A1 (de) 2020-05-11 2021-11-17 LeukoCom GmbH Neuer antikörper, der spezifisch an menschliches ceacam1/3/5 bindet, und dessen verwendung
CN115803062B (zh) 2020-06-03 2025-09-09 博泰康医药公司 滋养层细胞表面抗原2(trop-2)抗体
JP7789304B2 (ja) 2020-07-31 2025-12-22 バイオ－テラ ソリュ－ションズ，エルティーディー． Ｃｄ４７抗体及びその応用
JPWO2022075439A1 (de) 2020-10-08 2022-04-14
EP4393509A4 (de) 2021-08-26 2025-11-19 Perseus Proteomics Inc Promotor zur produktion reaktiver sauerstoffspezies (ros)
WO2023116911A1 (zh) 2021-12-24 2023-06-29 百奥泰生物制药股份有限公司 抗FRα抗体及其抗体药物偶联物和用途
CN119095873A (zh) 2022-03-14 2024-12-06 拉姆卡普生物伽马股份公司 用于靶向杀伤GPC3阳性恶性细胞的双特异性GPC3xCD28和GPC3xCD3抗体及其组合
JPWO2023204181A1 (de) 2022-04-19 2023-10-26
EP4635983A1 (de) 2024-04-15 2025-10-22 Ymmunobio AG Neuartiger antikörper mit spezifischer bindung an nptxr und verwendung davon

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT342197B (de) * 1975-02-20 1978-03-28 Ciba Geigy Ag Neues verfahren zur herstellung von 3-cephemverbindungen
JPS5214789A (en) * 1975-07-22 1977-02-03 Shionogi & Co Ltd Process for preparing 3-substiuted cephem compounds by ring closure
JPS56118085A (en) * 1980-02-25 1981-09-16 Takeda Chem Ind Ltd 2-methylcephalosporin derivative and its preparation
EP0124081A3 (de) * 1983-05-02 1986-11-26 Merck & Co. Inc. Substituierte Cephalosporinsulfone mit Antientzündungs- und Antidegenerativwirkung, sie enthaltende Zusammensetzungen und Verfahren zur Herstellung
US5132301A (en) * 1983-05-02 1992-07-21 Merck & Co., Inc. Substituted cephalosporin sulfones as anti-inflammatory and anti-degenerative agents
JPS60237061A (ja) * 1984-05-08 1985-11-25 Otsuka Chem Co Ltd アゼチジノン誘導体の製造法
NZ222399A (en) * 1986-11-12 1991-07-26 Merck & Co Inc Cephalosporin derivatives; pharmaceutical compositions and processes for preparation
GB8808701D0 (en) * 1988-04-13 1988-05-18 Erba Carlo Spa Beta-lactam derivatives
US5162521A (en) * 1991-06-06 1992-11-10 Bristol-Myers Squibb Company Processes for making cephems from allenylazetidinone derivatives

Also Published As

Publication number Publication date
US5470972A (en) 1995-11-28
WO1993016043A1 (en) 1993-08-19
EP0592677A4 (en) 1994-07-06
US5693792A (en) 1997-12-02
DE69331089T2 (de) 2002-07-18
EP0592677A1 (de) 1994-04-20
EP0592677B1 (de) 2001-11-07
DE69331089D1 (de) 2001-12-13

Similar Documents

Publication Publication Date Title
ATE208374T1 (de) Beta-laktam und cepham verbindungen und ihre herstellung
DE69020676D1 (de) Tricyclische Carbapenemverbindungen.
PT620225E (pt) Derivados de cefalosporina
TW256832B (de)
ATE181066T1 (de) Zwischenverbindungen zur herstellung von thioalkylthio cephalosporinderivaten
ATE141272T1 (de) Beta-lactam-verbindungen und ihre herstellung
ATE219085T1 (de) 2-beta-substituierte-6-alkylidenpenizillansäure derivate als beta-laktamase inhibitoren
KR950704333A (ko) 신규한 세펨 유도체(novel cephem derivatives)
ATE244248T1 (de) Herstellung von amino cephalosporansäurederivaten
ATE200674T1 (de) Herstellung von beta-lactamverbindungen und zwischenprodukte
ATE109764T1 (de) Beta-lactamverbindungen und deren herstellung.
DE69331249D1 (de) Verfahren zur Herstellung von (1'R,3S,4R)4-Acylthioazetidinonen

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee